

Sen. Meg Loughran Cappel

Filed: 4/14/2023

15

10300HB1565sam001

LRB103 25816 BMS 60088 a

AMENDMENT TO HOUSE BILL 1565
AMENDMENT NO Amend House Bill 1565 by replacing
line 23 on page 8 through line 11 on page 9 with the following:
"vaginal estrogen in its formulary.
(b) If a particular vaginal estrogen product or its
therapeutic equivalent version approved by the United States
Food and Drug Administration is determined to be medically
necessary, the issuer must cover that service or item pursuant
to the cost-sharing requirement contained in subsection (c).
(c) A policy subject to this Section shall not impose a
deductible, copayment, or any other cost sharing requirement
that exceeds any deductible, coinsurance, copayment, or any
other cost-sharing requirement imposed on any prescription
drug authorized for the treatment of erectile dysfunction

covered by the policy; except that this".